Zynex, Inc. Financial Update: Third Quarter Performance
Zynex, Inc. (NASDAQ: ZYXI), a leader in innovative medical technology focusing on non-invasive devices for pain management and rehabilitation, has recently announced its financial results for the third quarter ending September 30, 2025. This disclosure comes during a pivotal time as the company faces significant operational challenges.
Management’s Vision and Strategy
In a statement, Zynex’s Chief Executive Officer Steven Dyson expressed the new management team's dedication to overcoming the hurdles faced by the company since they joined in August. "We are implementing a strategy built around three pillars: enhancing compliance and integrity, addressing liquidity issues, and bolstering revenue and cash flow," he said.
As a proactive measure, Zynex has enlisted the services of Province, LLC, a globally recognized financial advisory firm, to explore various strategic alternatives. This includes investigating potential capital raising options and restructuring strategies to better position the company moving forward. Moreover, Paul Aronzon has been appointed as Chair of a Special Committee within the Board of Directors to navigate these strategic discussions effectively.
Compliance and Cash Preservation
In light of current financial constraints, Zynex has taken steps to preserve its cash reserves. The company has entered a thirty-day grace period to defer a $1.5 million interest payment due on its Convertible Notes, which amounted to $60 million and are set to mature in May 2026. Ongoing discussions with note holders aim to evaluate restructuring opportunities.
Financial Results Overview
The company reported net revenues of $13.4 million for the quarter, a marked decrease from $50.0 million in the same quarter of the previous year. This significant decline has been attributed primarily to issues related to the Tricare payment suspension, coupled with delayed reimbursements from various payers.
Furthermore, the workforce reductions implemented in earlier quarters have led to adverse effects on device orders and patient onboarding, exacerbating the revenue downturn during the third quarter of 2025.
Profitability Challenges
Gross profit for the quarter was $8.1 million, translating to 60% of revenue, down from 80%, equivalent to $39.8 million in Q3 2024. The decrease in profit margins is largely due to the ongoing Tricare revenue adjustments without a corresponding decrease in the cost of goods sold and reduced production volumes.
Sales and marketing expenses fell to $9.5 million, down 54% from $20.7 million the previous year, primarily due to a reduced sales force. General and administrative expenses also decreased, showing a decline to $11.8 million compared to $15.3 million in the prior year.
Net Loss and Future Perspectives
The net loss for Zynex for the three-month period totaled $42.9 million, or ($1.42) per share, a significant drop when considering the net income of $2.3 million or $0.07 per share reported in Q3 2024.
Adjusted EBITDA reflects a loss of $12.3 million for the third quarter, versus an adjusted EBITDA of $5.1 million a year prior, indicating a concerning trend that the management team is aiming to rectify swiftly.
Cash Flow and Forward Outlook
Cash flow from operations for the quarter showcased a net usage of $6.3 million. The current cash and cash equivalents reported as of September 30, 2025, were around $13.3 million, highlighting a need for strategic financial maneuvering.
Earnings Call Details
The company has scheduled its earnings call for November 18, 2025, to discuss the financial results in greater detail and provide guidance on future operations and strategic growth. Investors and stakeholders are invited to join this call to gain insights into the company’s path forward.
About Zynex, Inc.
Founded in 1996, Zynex, Inc. specializes in designing and manufacturing advanced medical devices that support pain management and rehabilitation efforts. Their products incorporate advanced technologies, which allow for non-invasive monitoring of various health parameters, including fluid and sepsis levels.
Frequently Asked Questions
What were Zynex's net revenues for Q3 2025?
Zynex reported net revenues of $13.4 million for the third quarter of 2025.
What challenges did Zynex face in terms of revenue?
The company faced significant declines in revenue primarily due to the Tricare payment suspension and workforce reductions affecting device orders and patient onboarding.
What is Zynex’s strategy moving forward?
Zynex aims to enhance compliance, address liquidity challenges, and improve revenue streams through strategic financial advisement.
When is the next earnings call?
The next earnings call is scheduled for November 18, 2025, at 9:00 AM Eastern Time.
What is Zynex's core business focus?
Zynex focuses on developing non-invasive medical devices for pain management and rehabilitation, enhancing the quality of patient care.
